Making sense of the biotech rumor mill
MSN Money - USA
The majority of Biogen's sales comes from Avonex, a multiple sclerosis drug that competes with Tysabri. Last year, Biogen's impressive overall sales growth ...
See all stories on this topic

Elan, Wyeth Accelerate
Wall Street Journal - USA
He also flagged a "series of Alzheimer's advancements" by year-end, shifting the focus away from Elan's multiple sclerosis drug Tysabri, which has up until ...
See all stories on this topic